IkT-001Pro not checked

Inhibikase Therapeutics

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
2 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Pulmonary Arterial Hypertension (PAH), Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH), CML
Main trialPhase 2
“This is a randomized, double-blind, multi-center, placebo-controlled dose-ranging clinical trial of two IkT-001Pro doses in patients with PAH designed to assess safety, tolerability and efficacy. It will enroll approximately 150 participants at up to 50 sites globally. The study consists of two parts, a 26 week placebo controlled treatment period (Part A) followed by a 36 month extension period (Part B).”In the company’s words, NCT06643143 on ClinicalTrials.gov

Other drugs for Pulmonary Arterial Hypertension (PAH)

All 24 drugs for Pulmonary Arterial Hypertension (PAH)

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 2Withdrawn 30 Jun 2027 A Phase 2 Study of IkT-001Pro in Pulmonary Arterial Hypertension (PAH)
Phase 1Completed 30 Jun 2024 A Dose Calibration Study Comparing IkT-001Pro to Imatinib Mesylate 400mg
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow IkT-001Pro

Following is part of Solo: you see every change to IkT-001Pro the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in